drugset / Trial / NCT04428372

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

NCT04428372

Phase 2/3 Completed 31 enrolled Brigham and Women's Hospital
RandomizedCrossoverQuadruple-blindPrevention

Summary

This proposal will measure the effects of mannitol administration versus placebo in hypotensive-prone, adult, maintenance hemodialysis patients with respect to changes in patient symptoms and blood pressure stability.

Timeline

Start
2021-04-06
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mannitol Diagnostic / imaging agent 0.25 g/kg Intravenous

Indications

No indication recorded.